Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)

被引：0
|
作者：
Nurden, A
Poujol, C
DurrieuJais, C
Besse, P
Jordan, R
Wagner, C
Nurden, P
机构：
[1] HOP CARDIOL,UMR 5533 CNRS,UNITE SOINS INTENS,IFR 4,PESSAC,FRANCE
[2] CENTOCOR LTD,MALVERN,PA
来源：
ATHEROSCLEROSIS | 1997年 / 134卷 / 1-2期
关键词：
D O I：
10.1016/S0021-9150(97)88959-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 41 条
  • [21] Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy
    Jubelirer, SJ
    Koenig, BA
    Bates, MC
    AMERICAN JOURNAL OF HEMATOLOGY, 1999, 61 (03) : 205 - 208
  • [22] Evidence for a decreased thrombin generation after platelet glycoprotein IIb/IIIa receptor antagonist c7E3 FAB infusion.
    Musso, R
    Cabibbo, S
    Cultrera, D
    Russo, M
    Russo, G
    Nicosia, A
    Mammana, C
    Tamburino, C
    Giustolisi, R
    BLOOD, 1997, 90 (10) : 1321 - 1321
  • [23] Adjunctive therapy with c7E3 (ReoPro) during high risk angioplasty of degenerated saphenous vein grafts
    Taniuchi, M
    Smith, SC
    Lasala, JM
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 : TC226 - TC226
  • [24] Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization
    Lincoff, AM
    Tcheng, JE
    Califf, RM
    Bass, T
    Popma, JJ
    Teirstein, PS
    Kleiman, NS
    Hattel, LJ
    Anderson, HV
    Ferguson, JJ
    Cabot, CF
    Anderson, KM
    Berdan, LG
    Musco, MH
    Weisman, HF
    Topol, EJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (03): : 286 - 291
  • [25] Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization
    Lincoff, AM
    Califf, RM
    Anderson, KM
    Weisman, HF
    Aguirre, FV
    Kleiman, NS
    Harrington, RA
    Topol, EJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (01) : 149 - 156
  • [26] STRIKING CLINICAL BENEFIT WITH PLATELET GP IIB/IIIA INHIBITION BY C7E3 AMONG PATIENTS WITH UNSTABLE ANGINA - OUTCOME IN THE EPIC TRIAL
    LINCOFF, AM
    CALIFF, RM
    ANDERSON, K
    WEISMAN, HF
    TOPOL, EJ
    CIRCULATION, 1994, 90 (04) : 21 - 21
  • [27] ACTIVATED CLOTTING TIME OF HEPARINIZED BLOOD IS INCREASED BY IN-VITRO PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR BLOCKADE WITH ANTIBODY C7E3 FAB
    AMMAR, T
    SARIER, K
    COLLER, BS
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1313 - 1313
  • [28] Free and total platelet glycoprotein IIb IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA
    Hézard, N
    Metz, D
    Nazeyrollas, P
    Nguyen, P
    Simon, G
    Daliphard, S
    Droullé, C
    Elaerts, J
    Potron, G
    THROMBOSIS AND HAEMOSTASIS, 1999, 81 (06) : 869 - 873
  • [29] Sudden onset of EDTA-dependent pseudothromboeytopenia after therapy with the glyeoprotein IIb/IIIa antagonist c7E3 Fab (Case report) (vol 79, pg 161, 2000)
    Stiegler, H
    Fischer, Y
    Steiner, S
    Strauer, BE
    Reinauer, H
    ANNALS OF HEMATOLOGY, 2000, 79 (04) : 226 - 226
  • [30] Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro
    Koestenberger, M
    Gallistl, S
    Cvirn, G
    Roschitz, B
    Muntean, W
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (05) : 425 - 432
12345